Reading Hospital/McGlinn Cancer Institute — West Reading, Pennsylvania

Reading Hospital/McGlinn Cancer Institute is a clinical research site located in West Reading, Pennsylvania, United States 19611.

Crixeo Health Trust Score: 53/100 (POOR). This profile has not yet been claimed by the site owner.

Reading Hospital/McGlinn Cancer Institute has participated in 2 clinical trials with 1 currently active.

Therapeutic areas: Non-Small Cell Lung Cancer, Multiple Myeloma.

Sponsors: RTOG Foundation, Inc., Janssen Research & Development, LLC.

Sponsor Feasibility Report

Trust Score: 53/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Reading Hospital/McGlinn Cancer Institute?

Reading Hospital/McGlinn Cancer Institute has a Crixeo Trust Score of 53/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Reading Hospital/McGlinn Cancer Institute conducted?

Reading Hospital/McGlinn Cancer Institute has 2 clinical trials on record, with 1 currently active. Their work covers Non-Small Cell Lung Cancer, Multiple Myeloma.

Is Reading Hospital/McGlinn Cancer Institute accredited by Crixeo Health?

Reading Hospital/McGlinn Cancer Institute has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Reading Hospital/McGlinn Cancer Institute?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.